Defeating Malaria Together
MMV & PARTNERS @ ASTMH 2019
68th Annual Meeting
Gaylord National Resort and Convention Center

Defeating Malaria Together
Defeating Malaria Together
**Scientific session 2**

**Maryland A (Ballroom Level)**  
**Thursday, 21 Nov., 8.00 am – 9.45 am**

**Malaria: Clinical Trials and Pre-Clinical Drug Development**

Chair/Co-Chair: **Francisco-Javier Gamo**, GlaxoSmithKline, Spain;  
**Phornpimon Tipthara**, Mahidol Oxford Tropical Medicine Research Unit, Thailand

Speakers and topics:

- A phase Ib study to investigate the antimalarial activity of M5717, a first-in-class inhibitor of Plasmodium elongation factor 2, using the induced blood stage *Plasmodium falciparum* malaria model,  
  **James McCarthy**, QIMR Berghofer Medical Research Institute, Australia

- A randomized, double-blind, placebo-controlled, phase Iib study to evaluate the safety, tolerability and chemoprotective activity of P218 against controlled human malaria infection by direct venous inoculation (DVI) of *Plasmodium falciparum* sporozoite (PfSPZ-DVI) in non-immune healthy adult volunteers,  
  **Mohamed Farouk Chughlay**, MMV, Switzerland

- Identification of Ivermectin Metabolites,  
  **Phornpimon Tipthara**, Mahidol Oxford Tropical Medicine Research Unit, Thailand

- Prophylactic efficacy of potent and broadly neutralizing, non-cross-competing fully human monoclonal antibodies targeting PfRH5,  
  **Lisa Purcell**, Regeneron Pharmaceuticals, USA

- Dissection of haplotype-specific drug response phenotypes in multiclinal malaria isolates,  
  **Standwell Nkhoma**, ATCC, USA

- Nanomolar Potency Inhibitors of the Malaria Purine Uptake Transporter Kill *Plasmodium falciparum* Parasites,  
  **Yvett Darcie Sosa**, Albert Einstein College of Medicine, USA

- Asparagine ethylenediamines as anti-malarial *Plasmodium*-selective proteasome inhibitors,  
  **Wenhu Zhan**, Weill Cornell Medical College, USA

---

**Symposium session 32**

**Maryland C (Ballroom Level)**  
**Thursday, 21 Nov., 1.45 pm – 3.30 pm**

**A Generation of Anti-Malarial Drug Candidates in Advanced Clinical Development Potential Future Treatments**

Chair/Co-Chair: **Wiweka Kaszubska**, MMV, Switzerland; **Stephan Duparc**, MMV, Switzerland

Speakers and topics:

- KAE609, a highly potent spiroindolone, in phase II, multi-center, open-label, dose-escalation study to determine safety of single (QD) and multiple (3 QD) doses given to adults with uncomplicated *Plasmodium falciparum* malaria,  
  **Ghyslain Mombo-Ngoma**, Centre de Recherches Medicales de Lambaréné, Gabon

- KAF156 and lumefantrine SDF combination phase II multicenter, open-label study to determine the effective and tolerable dose, given once daily for 1, 2, and 3-days to adults and children with uncomplicated *Plasmodium falciparum* malaria,  
  **Hoang Chau Nguyen**, Oxford University Clinical Research Unit (OUCRU), Vietnam

- MMV048 phase Iia open label study to assess safety and efficacy of a single dose treatment in adult patients with uncomplicated *Plasmodium vivax* or *falciparum* malaria monoinfection,  
  **Rezika Mohammed Yesuf**, University of Gondar, Ethiopia

- Phase II development of OZ439 (artefenomel)/ferroquine combination as a potential single dose cure for uncomplicated *Plasmodium falciparum* malaria,  
  **Grace Kaguthi**, Kenya Medical Research Institute (KEMRI)/ Centre for Respiratory Diseases Research (CRDR), Kenya
Symposium session 42

Maryland B (Ballroom Level)
Thursday, 21 Nov., 4.00 pm – 5.45 pm

Severe Malaria: Reducing Deaths by Improving Quality of Care
Chair: Hans Rietveld, MMV, Switzerland; Eric Halsey, CDC, USA

Speakers and topics:
- The epidemiological and health system challenges of severe malaria cases in remote, high-burden setting: Lessons from DR Congo, Nigeria and Uganda, Manuel Hetzel, Swiss Tropical and Public Health Institute, Switzerland
- A rapid assessment of severe malaria in Liberia, Victor Koko, National Malaria Control Programme, Liberia
- Update on severe malaria case-management, Jordan Burns, President’s Malaria Initiative, USA
- Preventing severe malaria deaths in Zambia, Tendayi Kureya, Development Data, Zambia

Symposium session 68

Potomac C (Ballroom Level)
Friday, 22 Nov., 10.15 am – 12.00 pm

Tafenoquine: New Drug for Chemoprophylaxis and Treatment of Relapsing Malaria
Chair/Co-Chair: Jimee Hwang, CDC, USA; Rice N. Price, Menzies School of Health Research, Australia

Speakers and topics:
- Tafenoquine: a new 8-aminoquinline for treatment and chemoprophylaxis, Mara Kreishman Deitrick, Walter Reed Army Institute of Research, USA
- Single dose treatment – the plan for tafenoquine roll out in Brazil, Marcus Lacerda, Fiocruz Amazonia/Tropical Medicine Foundation, Brazil
- Use of tafenoquine in the US – guidance from Centers for Disease Control and Prevention, Kathrine R. Tan, CDCP, USA
- Possible new indications for tafenoquine particularly in malaria elimination efforts, G. Dennis Shanks, Australian Defence Force Malaria and Infectious Disease Institute, Australia
Symposium session 82

Maryland B (Ballroom Level)
Friday, 22 Nov., 1.45 pm – 3.30 pm

Seasonal Malaria Chemoprevention (SMC): Current and Future Perspectives
Chair/Co-Chair: André Tchouatieu, MMV, Switzerland; Paul Milligan, London School of Hygiene and Tropical Medicines, UK

Speakers and topics:
- Implementation of SMC 7 years since the policy recommendation summary of progress in 13 countries from the SMC working group, Keziah L. Malm, National Malaria Control Program, Ghana
- Assessment of the frequency of molecular markers of resistance of *P. falciparum* to SP-AQ, before and after two years of deployment of SMC in 7 countries in the sub-Sahel region, Khalid Beshir, London School of Hygiene and Tropical Medicine, UK
- Adapting SMC: number of cycles and age range. Evidence from field studies and modelling, Matthew Cairns, London School of Hygiene and Tropical Medicine
- Additional interventions that could be added to seasonal malaria chemoprevention to reduce mortality and morbidity in children, Alassane Dicko, Malaria Research and Training Center, Mali

Symposium session 107

Maryland A (Ballroom Level)
Saturday, 23 Nov., 8.00 am – 9.45 Am

Can Pyronaridine-Artesunate Be Considered as a Potential Tool for Use in Malaria Elimination Settings?
Chair/Co-Chair: Stephan Duparc, MMV, Switzerland; Jane E. Achan, Medical Research Council, Gambia

Speakers and topics:
- Efficacy of pyronaridine-artesunate and single dose of primaquine in Eastern and Western Cambodia, area of multidrug resistance, Rithea Leang, National Center for Parasitology Entomology and Malaria Control (CNM), Cambodia
- Evaluation of the therapeutic efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated *falciparum* malaria in areas of artemisinin-resistant *falciparum* malaria in Vietnam, Ta Tinh, National Institute of Malariology, Parasitology and Entomology, Malaria Research and Treatment, Vietnam
- Efficacy of pyronaridine-artesunate in several sites of Myanmar, Kay T. Han, Ministry of Health and Sports, Department of Medical Research, Myanmar
- Efficacy of 1, 2 and 3 days of pyronaridine-artesunate in asymptomatic *Plasmodium falciparum* carriers from the Gambia and Zambia, Jane E. Achan, Medical Research Council (MRC) Unit, Gambia
Scientific Session 150

Maryland C (Ballroom Level)
Saturday, 23 Nov., 4.00 pm – 5.45 pm

Malaria: Updates and Innovations in Malaria Prevention

Chair/Co-Chair: Kent Kester, Sanofi Pasteur, US; Issaka Zongo, IRSS/INSTech, Burkina Faso

Speakers and topics:
- Kent Kester, Sanofi Pasteur, US; Issaka Zongo, IRSS/INSTech, Burkina Faso, Titus K. Kwambai, Kenya Medical Research Institute, Kenya
- Maternal and child malaria chemoprevention to enhance child development: A double-blinded randomized controlled trial, Paul Bangirana, Makerere University, Uganda
- Intermittent preventive treatment with sulfadoxine-pyrimethamine confers non-malarial effect on birthweight: Results from a mediation analysis, Michelle Roh, University of California San Francisco, US
- The duration of protection from azithromycin against malaria, pneumonia and gastroenteritis when given alongside seasonal malaria chemotherapy, Houndé, Burkina Faso and Bougouni, Mali, Mphatso Phiri, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Malawi
- The effectiveness of seasonal malaria chemoprevention (SMC) in the operational programming context of Guinea, Donal Bisanzio, RTI International, USA
- Optimizing delivery of Seasonal Malaria Chemoprevention (SMC) for children under 5 years of age: very high coverage consistently achieved through door-to-door campaigns in Burkina Faso, Issaka Zongo, IRSS/INSTech, Burkina Faso
- The effectiveness of repellent delivered through village health volunteers on malaria incidence in Southeast Myanmar: a stepped-wedge cluster-randomized controlled trial, Freya J. Fowkes, Burnet Institute, Australia

Scientific Session 165

Maryland C (Ballroom Level)
Sunday, 24 Nov., 8.45 am – 9.00 am

Malaria: Opportunities and Challenges for Providers and Policy-Makers in Malaria Control

Chair/Co-Chair: Kent Kester, Sanofi Pasteur, US; Moumouni Bonkoungou, Jhpiego, Burkina Faso

Speakers and topics:
- Clinical Management of Children with Malaria across 8 African Countries: A Cross-Sectional Assessment of Nationally Representative Direct Observation Data, Jessica Cohen, Harvard School of Public Health, USA
- Avian malaria: Tropical Deforestation and Host Specificity, Ravinder N. Sehgal, San Francisco State University, USA
- Laboratory quality control system for large-scale malaria serosurveys: Haiti 2017, Eric Rogier, CDCP, USA
- Risk of adverse pregnancy outcomes in women treated for malaria with dihydroartemesinin-piperaquine or quinine in the first trimester of pregnancy in Indonesia: a retrospective data analysis, Rukhsana Ahmed, Liverpool School of Tropical Medicine, UK
- What happens when the support ends? A comparison of private sector antimalarial market situations in Myanmar, Si Tu Thein, Population Services International, Myanmar
- Joint Efforts to Improve Malaria Control in Three Refugee Camps in Kigoma, Tanzania: Successes, Challenges and Lessons Learned, Shabani Kililwa Muller, PATH, Tanzania
- Mentoring, a New Approach to Improve Malaria Care in Burkina Faso, Moumouni Bonkoungou, PMI Improving Malaria Care Project, Burkina Faso
**Poster sessions**

**Poster Session B**

892 Correlations of *ex vivo* antimalarial drug sensitivities between standard and new antimalarial compounds in Tororo, Uganda, **Thomas Katairo**, Infectious Diseases Research Collaboration

**Poster Session C**

1595 Pharmacological Properties Of Piperaquine In Healthy Volunteers With Induced Blood-Stage *P. falciparum* Malaria Infection: A Mechanistic Modelling Approach, **Thanaporn Wattanakul**, Mahidol Oxford Tropical Medicine Research Unit, Thailand
**Poster Session B**

**Poster Session B**

892  Correlations of ex vivo antimalarial drug sensitivities between standard and new antimalarial compounds in Tororo, Uganda, *Thomas Katairo*, Infectious Diseases Research Collaboration

**Poster Session C**

Poster Session C

1595  Pharmacological Properties Of Piperaquine In Healthy Volunteers With Induced Blood-Stage *P. falciparum* Malaria Infection: A Mechanistic Modelling Approach, *Thanaporn Wattanakul*, Mahidol Oxford Tropical Medicine Research Unit, Thailand
**Poster Session B**

892  Correlations of ex vivo antimalarial drug sensitivities between standard and new antimalarial compounds in Tororo, Uganda,  
**Thomas Katairo**, Infectious Diseases Research Collaboration

**Poster Session C**

1595  Pharmacological Properties Of Piperaquine In Healthy Volunteers With Induced Blood-Stage *P. falciparum* Malaria Infection: A Mechanistic Modelling Approach,  
**Thanaporn Wattanakul**, Mahidol Oxford Tropical Medicine Research Unit, Thailand